



## COMPASS TRIAL RECRUITMENT CONTINUES BEYOND 1<sup>ST</sup> DECEMBER 2017.

Thank you for your participation in the Compass trial. Your support of the trial is providing important monitoring and quality information for the Renewal of the National Cervical Screening Program.

The decision to move Australia’s very successful Pap test screening program to 5 yearly HPV testing has been based on the best available evidence. In the case of the performance of cytology versus HPV testing in highly vaccinated cohorts of women, this has been done on the basis of comprehensive modelling as trial evidence in this group of women is not yet available.

The Compass trial seeks to confirm with research evidence the modelled performance of HPV testing compared with cytology testing. This remains important and among vaccinated women is the first trial in the world undertaking this comparison.

**Women joining Compass after December 2017 will continue to be randomly assigned to either 5 yearly HPV testing - (66%) or 2.5 yearly cytology testing (33%).**

*It is important to understand that at 5 years all women in the trial will be offered an exit HPV test.*

Women who test negative will therefore be invited for screening as follows:

	Recruitment	2 ½ years	5 years
Study arm A: cytology based screening	LBC	LBC	HPV
Study arm B: HPV based screening	HPV	10% of women will have LBC for safety monitoring	HPV

We acknowledge that women in the cytology arm of the trial will undergo an additional test and we value very highly their contribution to the trial as part of ongoing improvement of Australia’s National Cervical Screening Program.

Given the changes to the environment in which recruitment will be undertaken we have made adjustments to the participant’s information statement and consent form to reflect this. These adjustments have been approved by the Ethics committee. Translated versions in languages other than English are available on request.

**We do hope that you will continue to recruit women aged 25 to 37 years of age. It is important that from the 1<sup>st</sup> December you use the new participant information form and consent form included in this pack. Please dispose of or return any unused materials.**

For comprehensive clinical support, follow up advice and new management recommendations, please contact the VCS Liaison Physicians on (03) 9250 0300.

**A/Prof Marion Saville  
Executive Director  
Co-Principal Investigator**

For more information visit: [www.compasstrial.com.au](http://www.compasstrial.com.au)

